E M Beketova

Samara City Clinical Hospital No. 1 named after N.I. Pirogov, Samara, Russia.

2 publications 2022 – 2025 ORCID
RussiaIschemic StrokeFibrinolytic AgentsTissue Plasminogen ActivatorThrombolytic Therapy

What does E M Beketova research?

E M Beketova studies the use of Revelise (alteplase) for treating ischemic stroke, which occurs when a blood vessel supplying blood to the brain is blocked. Her research examines how well this medication works in everyday clinical situations, particularly among older patients and those with multiple health issues. By analyzing large patient groups and their recovery outcomes, she aims to improve treatment protocols for stroke, aiming for better patient recovery and quality of life.

Key findings

  • In the International PRIMA Study, nearly half (49.9%) of the 2,202 patients had good outcomes upon discharge after receiving Revelise for ischemic stroke.
  • After 90 days, the percentage of patients demonstrating good recovery increased to 66.4%.
  • The study showed that Revelise effectively reduces stroke-related disabilities, even for older patients and those with other comorbidities.

Frequently asked questions

Does Dr. Beketova study ischemic stroke?
Yes, Dr. Beketova focuses on the treatment of ischemic stroke using Revelise (alteplase).
What treatments has Dr. Beketova researched?
She has researched the effectiveness of Revelise for treating ischemic stroke.
Is Dr. Beketova's work relevant to older stroke patients?
Yes, her research shows that Revelise is effective for older patients and those with additional health issues.
What were the results of the International PRIMA Study?
The study found that nearly half of the patients had good outcomes after treatment, with this number rising significantly by 90 days.
How does Revelise help stroke patients?
Revelise helps by reducing stroke-related disabilities and improving recovery outcomes for patients.

Publications in plain English

[Thrombolytic Therapy for Ischemic Stroke with Revelise: Results of a Two-Year Follow-Up in the International PRIMA Study].

2025

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Shamalov NA, Khasanova DR, Marchenko SV, Soldatov MA, Azarova AG +46 more

Plain English
This study looked at how well and safely Revelise (alteplase), a medication for treating ischemic stroke (IS), works in real-life situations. It involved 2,202 patients, mostly around 68 years old, and found that nearly half (49.9%) of them had good outcomes when discharged, rising to 66.4% after 90 days. The results showed that Revelise effectively reduces stroke-related disabilities, even in older patients and those with other health issues. Who this helps: This benefits patients who suffer from ischemic strokes and the doctors treating them.

PubMed

[Intravenous thrombolytic therapy of ischemic stroke with the drug Revelisa in real clinical practice: results of the IVT-AIS-R study].

2022

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Soldatov MA, Klimov LV, Tolmachev AP, Kiseleva TV, Androfagina OV +17 more

Plain English
This study looked at the use of a drug called Revelisa to treat people who had ischemic strokes, which happen when blood flow to the brain is blocked. Researchers treated 550 patients and found that about 45% showed significant improvement in their condition one day after treatment. Additionally, 68.5% of patients had good recovery by the time they were discharged from the hospital after 90 days. Who this helps: This research benefits patients experiencing ischemic strokes and their healthcare providers by showing that Revelisa can effectively reduce symptoms and improve recovery.

PubMed

Publication data sourced from PubMed . Plain-English summaries generated by AI. Not medical advice.